[go: up one dir, main page]

PE20091464A1 - MODIFIED RELEASE PHARMULATION FORMULATION INCLUDING OXABISPIDINS - Google Patents

MODIFIED RELEASE PHARMULATION FORMULATION INCLUDING OXABISPIDINS

Info

Publication number
PE20091464A1
PE20091464A1 PE2009000255A PE2009000255A PE20091464A1 PE 20091464 A1 PE20091464 A1 PE 20091464A1 PE 2009000255 A PE2009000255 A PE 2009000255A PE 2009000255 A PE2009000255 A PE 2009000255A PE 20091464 A1 PE20091464 A1 PE 20091464A1
Authority
PE
Peru
Prior art keywords
pelets
compound
pharmulation
oxabispidins
modified release
Prior art date
Application number
PE2009000255A
Other languages
Spanish (es)
Inventor
Anders R Berggren
Hans Carlsson
Hans Jonsson
Kristina Roos
Erik Soderlind
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091464A1 publication Critical patent/PE20091464A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA DE LIBERACION MODIFICADA EN FORMA DE SISTEMA DE UNIDADES MULTIPLES TAL COMO CAPSULAS, TABLETAS O SACHETS, QUE COMPRENDE: i) PELETS DE LIBERACION INMEDIATA QUE COMPRENDEN UN COMPUESTO DE OXABISPIDINA TAL COMO (2-{7-[2-(4-CIANO-2-FLUOROFENOXI)ETIL]-9-OXA-3,7-DIAZABICICLO-[3.3.1]NON-3-IL}ETIL)CARBAMATO DE TERC-BUTILO (COMPUESTO A) Y ii) PELETS DE LIBERACION MODIFICADA QUE COMPRENDEN EL COMPUESTO A, RECUBIERTOS CON UNA MEMBRANA DE DIFUSION FORMADA POR UN POLIMERO FORMADOR DE PELICULA TAL COMO ETILCELULOSA O HIDROXIPROPILCELULOSA, DONDE LA RELACION ENTRE LOS PELETS DE TIPO i) Y ii) SE ENCUENTRA ENTRE 10:90 Y 90:10. DIHA FORMULACION ES UTIL EN EL TRATAMIENTO DE ARRITMIAS CARDIACASREFERRING TO A MODIFIED PHARMACEUTICAL RELEASE FORMULATION IN THE FORM OF A MULTIPLE UNIT SYSTEM SUCH AS CAPSULES, TABLETS OR SACHETS, WHICH INCLUDES: i) IMMEDIATE RELEASE PELETS THAT INCLUDE A COMPOUND (2- [TAL 4-CYANO-2-FLUOROPHENOXY) ETHYL] -9-OXA-3,7-DIAZABICYCLO- [3.3.1] NON-3-IL} ETHYL) TERC-BUTYL CARBAMATE (COMPOUND A) AND ii) MODIFIED RELEASE PELETS WHICH INCLUDE COMPOUND A, COATED WITH A DIFFUSION MEMBRANE FORMED BY A FILM-FORMING POLYMER SUCH AS ETILCELLULOSE OR HYDROXYPROPYLCELLULOSE, WHERE THE RELATIONSHIP BETWEEN THE 10:90 AND ii) TYPE PELETS IS FOUND AT THE 10:90 AND II) TYPE. SAID FORMULATION IS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

PE2009000255A 2008-02-22 2009-02-20 MODIFIED RELEASE PHARMULATION FORMULATION INCLUDING OXABISPIDINS PE20091464A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3064308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
PE20091464A1 true PE20091464A1 (en) 2009-10-24

Family

ID=40985767

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000255A PE20091464A1 (en) 2008-02-22 2009-02-20 MODIFIED RELEASE PHARMULATION FORMULATION INCLUDING OXABISPIDINS

Country Status (5)

Country Link
AR (1) AR070617A1 (en)
PE (1) PE20091464A1 (en)
TW (1) TW200940110A (en)
UY (1) UY31669A1 (en)
WO (1) WO2009105023A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (en) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 Esomeprazole magnesium enteric pill coated tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
CA2609938A1 (en) * 2005-06-13 2006-12-21 Astrazeneca Ab New oxabispidine compounds for the treatment of cardiac arrhythmias
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs

Also Published As

Publication number Publication date
WO2009105023A1 (en) 2009-08-27
TW200940110A (en) 2009-10-01
AR070617A1 (en) 2010-04-21
UY31669A1 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
AR072261A1 (en) PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS.
UY32816A (en) PHARMACEUTICAL FORMULATION BASED ON 1- [2- (2,1,3-BENZOTIADIAZOL-5-ILAMINO) -6 (2,6-DICLOROFENIL) -PIRIDO [2,3-D] PIRIMIDIN-7-IL] -3- TERT-BUTIL-URÉA
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
BRPI0911035B8 (en) pyrrolidinone glycokinase activators
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
UY30783A1 (en) DERIVATIVES OF SULFONIL-FENIL-2H- [1,2,4] OXADIAZOL-5-ONA, PROCESSES FOR ITS PREPARATION AND ITS USE AS PHARMACEUTICAL AGENTS
UY30759A1 (en) CHEMICAL COMPOUNDS
EP2246052A4 (en) RAPID DISINTEGRATION ORAL ADMINISTRATION TABLET CONTAINING IMIDAFENACIN
ECSP13012611A (en) PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2
UY32315A (en) PIPERIDINE COMPOUNDS AND USES OF THE SAME-596
ECSP099608A (en) SOLID PREPARATION THAT INCLUDES ALOGLIPTINA AND PIOGLITAZONA
AR065698A1 (en) SOLID PREPARATION
CL2012001366A1 (en) Carboxamida
CL2008000594A1 (en) USE OF COMPOUNDS DERIVED FROM HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND OTHER ACTIVE AGENTS; AND ITS USE TO TREAT DIABETES, CORONARY ARTERIAL DISEASE BETWEEN OTHER DISEASES.
MA37886B1 (en) New bicyclic pyridinones
CR10270A (en) MEDICINES CONTAINING FLUOROQUINOLONES
UY31141A1 (en) PIPERIDINE COMPOUNDS AND ITS USES
UY32674A (en) UREA HETEROCICLICAL DERIVATIVES AND THEIR EMPLOYMENT METHODS
DOP2010000374A (en) UREA HETEROCICLICAL DERIVATIVES AND THEIR EMPLOYMENT METHODS
CL2007003643A1 (en) PHARMACEUTICAL COMPOSITION OF AZIMILIDINE THAT INCLUDES 0.5% TO APPROXIMATELY 2.5% (W / W) OF WATER; AND USE FOR THE TREATMENT OF CARDIAC ARRITMIAS.
CL2012003011A1 (en) Oral disintegration tablet containing 1-30% acarbose, 40-90% of a water soluble vehicle and 1-50% of a water soluble vehicle, for the treatment of diabetes mellitus; and procedure for preparing oral disintegration tablets containing acarbose.
EP2865664A4 (en) NOVEL COMPOUND HAVING THE ABILITY TO INHIBIT ENZYME 11B-HSD1 OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
CO6382113A2 (en) CHEMICAL COMPOUNDS
CO6771403A2 (en) Acylbenzene derivative
EP2053038A4 (en) AMINOALCOHOL DERIVATIVE AND IMMUNODEPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal